Eli Lilly and Co (NYSE:LLY)
| 323.50 Delayed Data As of May 27 |  +10.04 / +3.20%Today’s Change | 195.50 Today|||52-Week Range 324.08 | +17.12% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $307.4B |
Company Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Contact Information
Eli Lilly & Co. Lilly Corporate Center Indianapolis Indiana 46285 |
Employees
Shareholders
| Mutual fund holders | 40.47% |
| Other institutional | 32.63% |
| Individual stakeholders | 11.84% |
Top Executives
| David A. Ricks | Chairman, President & Chief Executive Officer |
| Anat Ashkenazi | Chief Financial Officer & Senior Vice President |
| Daniel M. Skovronsky | Chief Scientific Officer & Senior Vice President |
| Diogo Rau | Senior VP, Chief Information & Digital Officer |
| Alonzo Weems | Senior VP, Chief Ethics & Compliance Officer |
